ReviewFrontiers in aging neuroscience2026
Glial lactate metabolism and transport in Alzheimer's disease.
Review in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Glycolysis: The Bridge Between Cellular Interaction and Alzheimer's Disease.Biomolecules · 2026Review
- Corticotropin-releasing factor (CRF) in brain aging: from mitochondrial dysfunction to inflammaging.Frontiers in aging neuroscience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Emerging evidence suggests that lactate, once considered merely a metabolic byproduct, plays vital roles in brain energy metabolism, signaling, and neuroprotection. In Alzheimer's disease (AD), increasing research has implicated disruptions in glial lactate metabolism and transport as key contributors to neurodegenerative progression. This review synthesizes recent findings on the dynamic metabolic profiles of astrocytes, oligodendrocytes, and microglia, with emphasis on their stage-specific glycolytic activities and their roles in neuronal energy support. We detail how these cellular metabolic behaviors and the intercellular lactate shuttle systems-mediated by monocarboxylate transporters (MCTs) and gap junctions-are altered in AD pathology. We highlight how these changes lead to a state of neuronal energetic crisis and, paradoxically, contribute to neuroinflammation. A clearer understanding of these complex glial lactate dynamics offers a promising perspective for novel AD biomarkers and therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.